Nektar Therapeutics is a biopharmaceutical company developing novel cancer therapies. Their oncology pipeline includes ONZEALD™ (etirinotecan pegol), a TOPO-1 inhibitor; bempegaldesleukin (NKTR-214), a CD122-preferential IL-2 pathway agonist; NKTR-262, a TLR 7/8 agonist and NKTR-255, an IL-15 agonist. Further information about the company and its drug development programs may be found online at http://www.nektar.com